What is ProMedTek?
ProMedTek operates at the intersection of medical device innovation and veteran-focused healthcare solutions. The company is best known for its Replexa+ therapy system, an FDA-cleared platform that leverages thermal shortwave diathermy to address chronic pain, muscle spasms, and mobility limitations. By providing a non-invasive, versatile treatment modality, ProMedTek has carved out a distinct niche in the therapeutic hardware market. Its commitment to the military community serves as both a social mission and a strategic market differentiator, allowing the firm to integrate its technology into specialized care environments where pain management is a critical clinical priority.
How much funding has ProMedTek raised?
ProMedTek has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ProMedTek
PPP
Public-Private Partnership
What's next for ProMedTek?
With the infusion of this latest capital, ProMedTek is expected to accelerate its market penetration and operational scaling. The company will likely focus on expanding the clinical adoption of the Replexa+ system, potentially targeting broader healthcare networks beyond its current veteran-centric footprint. Strategic priorities will likely include enhancing manufacturing capabilities to meet increased demand and investing in further clinical validation to support the efficacy of its diathermy technology. As the firm transitions through this late-stage growth phase, the focus will shift toward long-term sustainability and the potential for broader commercialization of its proprietary pain relief solutions.
See full ProMedTek company page
